ArticleFrontiers in cardiovascular medicine2022

Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.

Yaohui Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.